Papers/PMID:39044170
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.
The journal of headache and pain2024The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
propranolol — increases withdrawal due to adverse events
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.Finding“We found high certainty evidence that propranolol increases the proportion of patients who discontinue due to adverse events compared to placebo with a risk difference of 0.02 (95% CI 0.00 to 0.03); absolute risk difference: 20 more per 1,000 (95% CI 0 to 30).”
Quoted verbatim from European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.. - Study
- meta-analysis
- Participants
- 1,291
- Population
- Adults with migraine; meta-analysis of 20 randomized trials of oral propranolol versus placebo for migraine prophylaxis
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.2024PMID:39044170Permalink